Detailed explanation of the efficacy and effects of budesonide oral suspension (Eohilia)

Budesonide oral suspension (Eohilia) is an innovative treatment for eosinophilic esophagitis (EoE). Its core ingredient is budesonide, a synthetic glucocorticoid with significant anti-inflammatory effects. In eosinophilic esophagitis, the esophageal mucosa often undergoes chronic inflammation due to eosinophil infiltration, and patients often present with dysphagia, retrosternal pain, and discomfort while eating. The design concept of Eohilia is to reduce esophageal inflammation through local anti-inflammation, thereby improving patients' swallowing function and quality of life.

Different from traditional oral solid preparations, Eohilia is in the form of a suspension, allowing the drug to fully cover the esophageal mucosa during oral administration. It needs to be shaken well before use to dilute the drug solution and facilitate swallowing; after swallowing, the drug gradually returns to a thicker state in the esophagus, thus prolonging the contact time between the drug and the esophageal mucosa. This local mode of action not only increases the effective concentration of budesonide in the esophagus, but also reduces systemic absorption, thereby reducing the risk of systemic side effects. Overseas clinical studies have shown that locally acting budesonide can significantly reduce eosinophil infiltration, improve inflammatory indicators, and relieve patients' symptoms.

The anti-inflammatory mechanism of Eohilia mainly works by inhibiting the release of inflammatory mediators and reducing the accumulation of eosinophils and lymphocytes in the esophageal mucosa, thereby alleviating the local inflammatory response. At the same time, it can reduce the fibrosis trend of esophageal tissue and play a positive role in preventing long-term disease progression. This form of medication is especially suitable for children and adolescents aged 11 and above, as well as adult patients, and can improve compliance while ensuring efficacy. Through scientific administration methods, Eohilia maximizes the local anti-inflammatory effect of budesonide, making it one of the important choices for the daily management of patients with eosinophilic esophagitis.

Reference materials:https://www.eohilia.com/